Acquire an India-based Diagnostic and Healthcare test facility provider that is looking to sellout.
Posted By - Investment Banker
Posted date - 27/09/2022
BUSINESS BRIEF
The company is a provider of Diagnostic and Healthcare Tests Facilities having presence in Molecular and In vitro diagnostics. A wide Variety of Tests are conducted under:
- Molecular Pathology
- Cytogenetics
- Histopathology & Hematology
- Prognostic and Monitoring services
Scope of Testing expanded to:
- Biochemistry
- Hematology
- Immunology and Microbiology
- Expanding into Specialized Cancer Diagnosis
Operational Highlights:
- Routine lab holds testing capacity of 560 parameter in 1 hour
- Operates in B2B and B2C segments
- The samples are collected via home collection and walk-ins
Testing Segments:
- Cancer Testing
- Covid Testing
- Other Testing
Highlights:
- High Margins
- Low B2B Price
- Preventive Care Packages
- Pan India presence
- Fully Automated labs
Projections( In INR Crores):
Sales:
2023-9.5 (34% EBITDA Margin)
2024-10.2 (39% EBITDA Margin)
2025-11.5 (40% EBITDA Margin)
Proposal
Industry
Hospitals and Healthcare
Sub Industry
Diagnostic Imaging Centres
Deal Size
INR 9 - 10 Cr
Motives For Sellout
Strategic Realignment
Management is open to continue with the business for handholding the new investor/buyers
Business Operation Information
Industry
Hospitals and Healthcare
Sub-Industry
Diagnostic Imaging Centres
Division
Division`s Buyers/Customers
Division`s Products/Services
Industry
Hospitals and Healthcare
Sub-Industry
Diagnostic Imaging Centres
Division
Division`s Buyers/Customers
Division`s Products/Services
Division`s Products/Services
Division`s Products/Services
Division`s Products/Services
Financial Information |
2019 (in Cr) | 2020 (in Cr) | 2021 (in Cr) | 2022 (in Cr) |
|---|---|---|---|---|
Sales |
N.D | N.D | N.D | INR 7.56 Cr |
EBITDA |
N.D | N.D | N.D | N.D |
PAT |
N.D | N.D | N.D | N.D |
TOTAL DEBT |
N.D | N.D | N.D | N.D |
Business Documents
Recommended Deals
India-based Healthcare - AI-assisted disease management platform is looking to s...
Sales (2022): INR 7.56 Cr
The company offers an AI assisted disease management platform that reduces cost ...
₹ 40 - 50 Cr
Western India-based Commercial Production of Orthopaedic implants and instrument...
Sales (2022): INR 7.56 Cr
The Company has its Commercial Production of Orthopaedic implants and instrument...